DELETION OF TACI PROTECTS AGAINST AUTOIMMUNE DISEASE IN LUPUS-PRONE MOUSE MODELS WITH DIFFERENT DISEASE MECHANISMS

EX Lim*, W Figgett, F Mackay, M Hibbs. Peter Doherty Institute- The University of Melbourne, Department of Immunology, Melbourne, Australia; Monash University, Department of Immunology and Pathology, Melbourne, Australia

Background and aims Systemic lupus erythematosus (SLE) is a debilitating autoimmune disease driven by production of auto-antibodies which targets various organs including the kidney. SLE is notoriously heterogeneous, arising from numerous possible mechanisms and there is no current efficient treatment. Many of these distinct mechanisms can be reproduced in different mouse models of SLE. Excess production of the B cell activating factor of the TNF family (BAFF) has been previously implicated as a disease-associated factor in a subset of SLE patients, particularly by signalling through transmembrane activator and cyclophilin ligand interactor (TACI) to drive pro-inflammatory autoantibody production. We investigated if deletion of TACI in various mouse models of SLE would be protective.

Methods Flow cytometry was used to characterise B cell and antibody-producing plasma cell subsets in these mouse models. Autoantibody detection and serum cytokine levels were measured using ELISA whilst kidney histopathology was assessed using paraffin-embedded kidney sections.

Results Indeed, the results show that deletion of TACI in BAFF-transgenic mice and other mouse models with separate disease mechanisms, prevented disease by restricting autoantibody production and decreased kidney pathology. Loss of TACI protected these mice from disease whilst maintaining B cell numbers.

Conclusions These data provide increased support for choosing TACI as a key target for therapeutic intervention, which may be applicable in treating multiple subtypes of SLE. This would offer treatment efficacy without the serious adverse events linked with extensive loss of B cells.

TERIFLUNOMIDE SODIUM CAN EFFECTIVELY CONTROL PROGRESS OF SPONTANEOUS LUPUS OF MRL/LPR MOUSE

C Ma, B Qiu, L He, L Bao, L Sun, L Zhang, N Liu, F Xiao*. Cinkate Pharmaceutical Intermediates Co.-Ltd., development centre, shanghai, China

Background and aims Teriflunomide sodium (CK8) is the sodium salt of the metabolites of the leflunomide. Leflunomide has been approved for the treatment of lupus nephritis by CFDA. The aim of the study was to evaluate the therapeutic effect of CK8 on the course of disease in SLE-prone MRL/lpr mice, compared with leflunomide and glucocorticoid.

Methods Ten to eleven-weeks-old female mice displaying clinical symptoms of SLE were given CK8 (20 mg/kg, 30 mg/kg, 40 mg/kg) gavage once a day for 8 weeks. Control mice received gavage of leflunomide (30 mg/kg), Prednisone Acetate (2 mg/kg) or vehicle. Survival, proteinuria, lupus-like skin lesion, lymphoid organ, level of anti-dsDNA antibodies and IL-17 in serum, double negative (DN) T cells and regulatory T cell were analysed.

Results The results show that after treatment 8 weeks, 3 of 12 mice in vehicle control group led to death because of severe SLE, but mice all survived in CK8 30 mg/kg group. CK8 can effectively improve the skin lesions, swollen of lymph nodes and spleen and other symptoms of lupus, reduce proteinuria (figure 1), the level of serum anti-dsDNA antibody (figure 2) and IL-17 (figure 3), and a significant dose-response relationship. Further study found that treatment with CK8 can significantly reduce glomerular nephritis and interstitial nephritis lesions in MRL/lpr mouse, but leflunomide without obvious improvement. CK8 can significantly decrease proportion of the DN T cells, increase proportion of regulatory T cells.

Conclusions The results suggest that the CK8 can effectively control progress of spontaneous lupus of MRL/lpr mouse, improve the symptoms and signs.

HYPER-ACTIVATION AND IN SITU RECRUITMENT OF INFLAMMATORY V δ2 T CELLS CONTRIBUTES TO DISEASE PATHOGENESIS IN SYSTEMIC LUPUS ERYTHEMATOSUS

W Mo*, S Yin, X Zhang. Beijing peking union medical college hospital, rheumatology, Beijing, China

Abstract 99 Figure 1

Abstract 99 Figure 2

Abstract 99 Figure 3
**Background and aims** Vδ2 T cells have predominantly been investigated in tumour immuno-surveillance and the host defense against viral invasion. The precise role of Vδ2 T cells in the pathogenesis of SLE remains elusive.

**Methods** We measured the proportion of peripheral Vδ2 T cells as well as the status and chemokine receptor expression profiles in SLE patients and healthy control (HC). In addition, Vδ2 T cell infiltration in the kidneys of patients with lupus nephritis was examined.

**Results** The percentage of peripheral Vδ2 T cells in new-onset SLE was decreased, and negatively correlated with the SLE Disease Activity Index score and the severity of proteinuria. These cells had a decreased apoptosis but an increased proliferation, and they showed increased accumulation in SLE kidneys. Moreover, IL-21 production and CD40L, CCR4, CCR7, CCR8, CXCRL1 and CX3CR1 expression in Vδ2 T cells from SLE patients was significantly higher than from HC (p<0.05), and these factors were down-regulated in association with the repopulation of peripheral Vδ2 T cells in patients who were in remission (p<0.05). In addition, anti-TCR Vδ2 antibodies activation significantly upregulated these chemokine receptors on Vδ2 T cells from HC, and this effect was blocked by inhibitors of PLC-γ1, MAPK/Erk, and PI3K signalling pathways.

**Conclusions** The distribution and function status of Vδ2 T cells from SLE patients are abnormal, and these aberrations may contribute to disease pathogenesis.

**Abstracts**

101 **GILZ REPRESENTS A CHECKPOINT LIMITING CYCLICAL EXACERBATION OF INFLAMMATION IN SLE BY TYPE I INTERFERON**

C Nataraja*, S Jones, E Morand. Monash Health, Medicine, VIC, Australia

10.1136/lupus-2017-000215.101

**Background and aims** Glucocorticoid-induced Leucine Zipper (GILZ) is a GC-inducible gene with multiple immune-regulatory functions, and GILZ deficiency in mice results in the development of a lupus-like phenotype. In Systemic Lupus Erythematosus (SLE), plasmacytoid dendritic cells (pDCs) are major producers of Type 1 interferons (IFNα) in response to nucleic acid-containing immune complexes. GILZ inhibits activation of B cells, T cells and other myeloid cells and we studied whether GILZ regulates interferon secretion by pDC.

**Methods** We conducted a study of GILZ expression in human peripheral blood mononuclear cells in-vitro and in-vivo study in GILZ KO mouse model to analyse the regulatory function of GILZ.

**Results** Our data suggests that loss of GILZ up-regulates type 1 IFN production by pDC in response to TLR7 and TLR9 stimulation. Basal GILZ expression was lower in pDCs than in other myeloid cell types and the relative deficiency of GILZ expression in pDC may predispose these cells to rapid activation and interferon production in SLE. Moreover, GILZ appears to be rapidly downregulated by type 1 interferons and in SLE patients, the level of GILZ, normalised by prednisolone dose, negatively correlated with SLEDAI. Thus, down-regulation of GILZ by type I interferon may allow heightened interferon release by pDC, and this mechanism potentially leads to amplification of inflammation and cyclical disease flare-ups in lupus patients.

**Conclusions** Restoration of GILZ may be a potential therapeutic strategy that could reduce the GC dependence in SLE, a strategy that is appealing since GILZ has thus far not recapitulated any of the metabolic effects of GC.

102 **INHIBITORY EFFECT OF RESVERATROL ON OXIDATIVE STRESS IN MURINE MODEL OF SYSTEMIC LUPUS ERYTHEMATOSUS**

N Pannu*, A Bhatnagar. Panjab University, Biochemistry, Chandigarh, India

10.1136/lupus-2017-000215.102

**Background and aims** Systemic lupus erythematosus is a systemic autoimmune inflammatory disease where therapeutics are associated with various side effects. As dietary factors have been associated in the prevention of different diseases this study aimed to exploit resveratrol, a polyphenol derived from peaches, grapes, etc as a dietary factor supporting therapeutics by using its antioxidative properties in the management of oxidative stress in a pristane induced murine model of lupus.

**Methods** The model was established by injecting 0.5 ml of pristane intra-peritoneally and oxidative stress was assessed.